DGIdb - ATM Gene Record

ATM 472 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

472
ATM SERINE/THREONINE KINASE
ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
607585
795
ENSG00000149311
OTTHUMG00000166480
Q13315
ATM_HUMAN
SERINE-PROTEIN KINASE ATM
69
SERINE-PROTEIN KINASE ATM (EC 2.7.1.37) (ATAXIA TELANGIECTASIA MUTATED) (A-T, MUTATED). [SOURCE:UNIPROT/SWISSPROT;ACC:Q13315]
PA61
T97196

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Interpro Acc	IPR000403
Interpro Short Name	PI3/4_kinase_cat_dom
Uniprot Status	Swiss-Prot
Interpro Name	Phosphatidylinositol 3-/4-kinase, catalytic domain
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	PHOSPHATIDYLINOSITOL 3 KINASE
Interpro Type	Domain
Gene Biotype	PROTEIN_CODING

(16 More Sources)

Gene Categories: Category Details

TUMOR SUPPRESSOR
KINASE
SERINE THREONINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
PHOSPHATIDYLINOSITOL 3 KINASE
CLINICALLY ACTIONABLE
ENZYME

Publications:

Pedersen AJT et al., 2018, The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial., Basic Clin Pharmacol Toxicol
Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood
Navrkalova V et al., 2013, ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin., Haematologica
Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
Kwok et al., 2016, ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells., Blood
Vendetti et al., 2015, The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo., Oncotarget
Kubota et al., 2014, Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines., Cell Cycle
Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.
Williamson et al., 2010, ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors., Mol. Cancer Ther.
Bang et al., 2015, Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer., J. Clin. Oncol.
Schmitt et al., 2017, ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma., Cancer Res.
Moroi et al., 1975, Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase., Biochem. Pharmacol.
Poole-Wilson et al., 1975, Effect of pH on ionic exchange and function in rat and rabbit myocardium., Am. J. Physiol.
de Bono J et al., 2020, Olaparib for Metastatic Castration-Resistant Prostate Cancer., N Engl J Med
Eich et al., 2013, Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide., Mol. Cancer Ther.
Kamal A et al., 2012, Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents., Bioorg Med Chem
Won et al., 2006, Small molecule-based reversible reprogramming of cellular lifespan., Nat. Chem. Biol.
Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget
Kato et al., 2017, RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients., Clin. Cancer Res.
Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Patel et al., 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells., Proc. Natl. Acad. Sci. U.S.A.
Riabinska et al., 2013, Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors., Sci Transl Med
Smida et al., 2016, MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated., Nat Commun

BENDAMUSTINE ATM

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
20739657

Sources:
JAX-CKB
CHEMBL1086377 ATM

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23761041

Sources:
CIViC
AZD-0156 ATM

Interaction Score: 1.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
SCHISANHENOL ATM

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
KU-55933 ATM

Interaction Score: 1.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16767085

Sources:
DTC
NAFTIFINE HYDROCHLORIDE ATM

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CERALASERTIB ATM

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
26563132 26517239

Sources:
JAX-CKB
2X-121 ATM

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB
CHEMBL606460 ATM

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OLAPARIB ATM

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB
VELIPARIB ATM

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21300883 27638859

Sources:
ClearityFoundationBiomarkers JAX-CKB
ESTRADIOL BENZOATE ATM

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL74852 ATM

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1329443 ATM

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
BERZOSERTIB ATM

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
28363999

Sources:
JAX-CKB TTD
HEPTACHLOR ATM

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PERMETHRIN ATM

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL601933 ATM

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ENPIROLINE ATM

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUNARIZINE DIHYDROCHLORIDE ATM

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL375673 ATM

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TALAZOPARIB ATM

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
23881923

Sources:
JAX-CKB
AZD-6482 ATM

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type chronic lymphocytic leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26563132

Sources:
JAX-CKB
IBRUTINIB ATM

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Ibrutinib

Indication/Tumor Type chronic lymphocytic leukemia

Response Type sensitive

PMIDs:
26563132

Sources:
JAX-CKB
MITOTANE ATM

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
NIRAPARIB ATM

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
BINIMETINIB ATM

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
28514312

Sources:
JAX-CKB
TEMOZOLOMIDE ATM

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23960094

Sources:
CIViC
FLUDARABINE ATM

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
20739657

Sources:
JAX-CKB
PROTOPORPHYRIN DISODIUM ATM

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL374632 ATM

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DITHIAZANINE IODIDE ATM

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ISOVELLERAL ATM

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL1519374 ATM

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PHLORETIN ATM

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SELUMETINIB ATM

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27922010

Sources:
CIViC
CHEMBL299853 ATM

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOLONIUM CHLORIDE ATM

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METFORMIN ATM

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28834135

Sources:
PharmGKB
EVEROLIMUS ATM

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vandetanib + Everolimus

Indication/Tumor Type thyroid medullary carcinoma

Response Type predicted – sensitive

PMIDs:
27683183

Sources:
JAX-CKB
STREPTONIGRIN ATM

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRAMETINIB ATM

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27922010

Sources:
CIViC
METHYLTHIONINIUM CHLORIDE ATM

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL578061 ATM

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ETOPOSIDE ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22364746

Sources:
DTC
IRINOTECAN ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

combination therapy Irinotecan + Veliparib

PMIDs:
27638859

Sources:
JAX-CKB
VANDETANIB ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vandetanib + Everolimus

Indication/Tumor Type thyroid medullary carcinoma

Response Type predicted – sensitive

PMIDs:
27683183

Sources:
JAX-CKB
DOXORUBICIN ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23585524

Sources:
CIViC PharmGKB
RUCAPARIB ATM

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
PACLITAXEL ATM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Olaparib + Paclitaxel

Indication/Tumor Type stomach cancer

Response Type predicted – sensitive

PMIDs:
26282658

Sources:
JAX-CKB
DIPYRIDAMOLE ATM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN ATM

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
26517239

Sources:
JAX-CKB
CYCLOPHOSPHAMIDE ATM

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ATM

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000149311
- Version: 101_38
Alternate Names:

ATM Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
HopkinsGroom: Q13315
- Version: 11-September-2012
Alternate Names:

SERINE-PROTEIN KINASE ATM Uniprot Protein Name

Q13315 Uniprot Accession

ENSG00000149311 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Interpro Acc IPR000403

Interpro Short Name PI3/4_kinase_cat_dom

Gene Categories:

DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE

Publications:

RussLampel: ENSG00000149311

Version: 26-July-2011

Alternate Names:

SERINE-PROTEIN KINASE ATM (EC 2.7.1.37) (ATAXIA TELANGIECTASIA MUTATED) (A-T, MUTATED). [SOURCE:UNIPROT/SWISSPROT;ACC:Q13315] Description

ENSG00000149311 Ensembl Gene Id

ATM Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

JAX-CKB: ATM

Version: 27-September-2017

Alternate Names:

472 CKB Entrez Id

ATM CKB Gene Synonym

AT1 CKB Gene Synonym

Gene Info:

Publications:

Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood

Kwok et al., 2016, ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells., Blood

Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.

PharmGKB: ATM
- Version: 18-August-2020
Alternate Names:

PA61 PharmGKB ID

Gene Info:

Publications:

Pedersen AJT et al., 2018, The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial., Basic Clin Pharmacol Toxicol

CIViC: ATM

Version: 14-September-2020

Alternate Names:

472 Entrez Gene ID

69 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE, CLINICALLY ACTIONABLE

Publications:

Riabinska et al., 2013, Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors., Sci Transl Med

Navrkalova V et al., 2013, ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin., Haematologica

Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood

DTC: ATM

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Won et al., 2006, Small molecule-based reversible reprogramming of cellular lifespan., Nat. Chem. Biol.

Kamal A et al., 2012, Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents., Bioorg Med Chem

HingoraniCasas: ENSG00000149311
- Version: 31-May-2017
Alternate Names:

ENSG00000149311 Gene Symbol

ATM Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
OncoKB: ATM
- Version: 23-July-2020
Alternate Names:

472 OncoKB Entrez Id

ATC OncoKB Gene Synonym

ATD OncoKB Gene Synonym

Gene Info:

Publications:
HumanProteinAtlas: ATM
- Version: 19.3
Alternate Names:

ENSG00000149311 Ensembl Gene ID

ATA Human Protein Atlas Gene Synonym

ATC Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
Tempus: ATM
- Version: 11-November-2018
Alternate Names:

ATM Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: ATM
- Version: 27-Jun-2013
Alternate Names:

472 Gene ID

AT1 dGene Synonym

ATA dGene Synonym

Gene Info:

Gene Categories:

KINASE, SERINE THREONINE KINASE

Publications:
TTD: ATM serine/threonine kinase
- Version: 2020.06.01
Alternate Names:

ATM TTD Gene Abbreviation

T97196 TTD Target ID

Gene Info:

Publications:
Pharos: ATM
- Version: 01-February-2022
Alternate Names:

Serine-protein kinase ATM Gene Name

Q13315 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
MskImpact: ATM
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationBiomarkers: ATM
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: ATM
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: ATM
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
GO: ATM
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

TUMOR SUPPRESSOR, SERINE THREONINE KINASE

Publications:
Oncomine: ATM
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

combination therapy	AZD6738 + Cisplatin
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	stomach cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	chronic lymphocytic leukemia
Response Type	sensitive
Approval Status	Preclinical

combination therapy	AZD6738 + Ibrutinib
Indication/Tumor Type	chronic lymphocytic leukemia
Response Type	sensitive

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Clinical Study

combination therapy	Vandetanib + Everolimus
Indication/Tumor Type	thyroid medullary carcinoma
Response Type	predicted – sensitive

combination therapy	Olaparib + Paclitaxel
Indication/Tumor Type	stomach cancer
Response Type	predicted – sensitive

SERINE-PROTEIN KINASE ATM	Uniprot Protein Name
Q13315	Uniprot Accession
ENSG00000149311	Ensembl Gene Id

SERINE-PROTEIN KINASE ATM (EC 2.7.1.37) (ATAXIA TELANGIECTASIA MUTATED) (A-T, MUTATED). [SOURCE:UNIPROT/SWISSPROT;ACC:Q13315]	Description
ENSG00000149311	Ensembl Gene Id
ATM	Display Id

472	OncoKB Entrez Id
ATC	OncoKB Gene Synonym
ATD	OncoKB Gene Synonym

ENSG00000149311	Ensembl Gene ID
ATA	Human Protein Atlas Gene Synonym
ATC	Human Protein Atlas Gene Synonym

ATM Gene Record

ATM 472 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 20739657

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23761041

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16767085

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD6738 + Cisplatin Indication/Tumor Type non-small cell lung carcinoma Response Type sensitive

PMIDs: 26563132 26517239

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

PMIDs: 26513298

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung adenocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type stomach cancer Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 21300883 27638859

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type lung adenocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 28363999

Sources: JAX-CKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
20739657

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
23761041

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16767085

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Cisplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
26563132 26517239

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
24841718 26510020 20124459 20739657 26282658 28363999 8 2014 32343890

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21300883 27638859

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
28363999

Sources:
JAX-CKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
23881923

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type chronic lymphocytic leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
26563132

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Ibrutinib

Indication/Tumor Type chronic lymphocytic leukemia

Response Type sensitive

PMIDs:
26563132